Search PubMed⌕ Search

Biomedical subjects

A Morganti

Publications and source records attributed to A Morganti.

At least 91 records · Page 5Linked to original sources
PubMed1978

Beta-blockade and blood-levels after low-dose oral propranolol: The hepatic "first-pass" threshold revisited.

Heart-rate, arterial pressure, and plasmarenin activity were determined in six normal subjects at rest and after an injection of 8 microgram isoprenaline with and without prior propranolol administered orally in a dose of 5 mg 8-hourly for a total of five doses. After propranolol, resting heart-rate, systolic pressure, and plasma-renin activity all fell significantly (P less than 0.05 to less than 0.001). When the isoprenaline-induced changes of heart-rate, diastolic pressure, and plasma renin activity without propranolol were compared to those with propranolol, these responses were greatly diminished (P less than 0.01 to less than 0.001). The percent blockade by propranolol of the isoprenaline-induced changes ranged from 65% for diastolic pressure to 77% for heart rate and 78% for plasma-renin activity. Propranolol levels determined by conventional fluorometry were below accurate detection limits, whereas those determined by gas-liquid chromatography ranged from 2.3 to 8.5 ng/ml. These findings, which demonstrate beta-blockade with low-dose propranolol, are not consistent with the existence of a postulated threshold for the hepatic "first-pass effect" in man, which is said to require saturation by single doses of 30 mg or more before propranolol enters the systemic circulation.

Administration, Oral↗
PubMed1978

Considerations on physiopathological approaches to the treatment of hypertension.

1. Two main physiopathological approaches to the treatment of hypertension are discussed, the first based on renin profiling and the second on haemodynamic measurements. 2. Reduction in plasma renin activity does not appear to be a clinically important mechanism in the hypotensive effect of beta-adrenergic blockers and of alpha-methyldopa. In particular, alpha-methyldopa has been found equally effective as a hypotensive agent both in normal renin and in low renin hypertensive patients. 3. Diuretics are certainly possessed of a renin-stimulating action, but in most patients this action does not obscure the hypotensive effect of these drugs. 4. Responders and non-responders to the hypotensive activity of beta-adrenergic blockers do not differ among them in their control haemodynamics.

Adrenergic beta-Antagonists↗
PubMed1977

Plasma renin activity in primary and secondary depression.

Plasma renin activity (PRA), both in supine and standing position, was investigated in primary and secondary depressed patients. After orthostatic stimulation (standing position) primary depressed patients showed PRA values significantly lower than did those with secondary depression. The authors stress the importance of the peripheral sympathetic system in the control of renin release and discuss the data obtained in the light of some evidence in the literature indicating a possible impairment of transmitter turnover in central and peripheral noradrenergic synapses in the pathogenesis of primary depression.

Adjustment Disorders↗
PubMed1976

Control of renin release: a review of experimental evidence and clinical implications.

Present knowledge of the mechanisms regulating release of renin is reviewed with particular emphasis on neural factors. Evidence is given for a direct effect of renal innervation on beta adrenergic receptors in juxtaglomerular cells, and for the involvement of reflex release of renin in conditions such as tilting and acute salt depletion. Participation of neural and nonneural mechanisms of control is also shown to occur in other conditions, such as aortic constriction and hemorrhage. The view is held that neural sympathetic factors might explain some of the renin disturbances found in essential hypertension. First, in patients with high renin hypertension part of the hypertension is renin-dependent, and these pressor levels of renin seem to be neurally induced since they can commonly be suppressed by beta adrenoreceptor blocking agents. Second, the hypothesis is presented that patients with low renin hypertension, at least those who have no volume disturbance, have a blunted sympathetic control of renin release. Therefore a sufficiently precise test of sympathetic activity, and possibly of body fluid volumes, should be associated with renin profiles for a better understanding of the pathophysiology of arterial hypertension and as a better guide to therapeutic management. Indeed, most of the available antihypertensive drugs act on sympathetic activity, body fluid volume or renin, and this multifaceted profile would provide more rational guidelines for treatment.

Adrenergic beta-Antagonists↗
PubMed1976

Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment.

Propranolol blood and plasma levels were measured after a single oral dose of 40 mg in patients with chronic renal failure, in patients undergoing regular dialysis treatment, and in healthy volunteers. Peak levels were observed in all cases within 1.5 to 3 hours. However, peak blood and plasma concentrations of propranolol in the chronic renal failure group were 2- to 3-fold higher (161 +/- 41 ng/ml) than those observed in the dialysis patients (47 +/- 9 ng/ml) and in the healthy volunteers (26 +/- 1 ng/ml). The apparent plasma clearance was also significantly reduced in the patients with chronic renal failure. The data suggest a reduced hepatic extraction in chronic renal failure patients. A significant increase in the fraction of the dose available to the systemic circulation was also found, together with a modification of apparent plasma half-life and volume of distribution in regular dialysis patients during the dialysis day as compared with the after-dialysis day. No extraction of propranolol by the dialyzer was noticed. Marked fluctuations in propranolol blood concentrations were also observed in patients on regular dialysis following continuous propranolol treatment. The suppressive effect of propranolol on plasma renin activity did not fully correlate with the hypotensive effect of the drug. On the basis of the reported data, propranolol should be used with great caution and at low doses in chronic renal failure.

Adult↗
PubMed1975

Plasma renin activity in depressed patients treated with increasing doses of lithium carbonate.

Plasma renin activity (PRA) was measured in the supine position and after active upright stance in patients with endogenous depression and in a group of healthy volunteers serving as controls. In the depressed patients, PRA was further investigated in the same conditions during treatment with increasing doses of lithium carbonate. Basal PRA values were lower in depressed patients than in normal controls, particularly in the upright stance, and tended to rise gradually during lithium therapy. These findings suggest that lithium may work as a stimulant of the renin-angiotensin system, and possibly as an antidepressant, by way of producing functional activation of the norepinephrine system independent of its action on the water and electrolyte balance.

Adult↗
PubMed1975

Hypotensive and renin-suppressing activities of propranolol in hypertensive patients.

1. In patients with mild or moderate essential hypertension, oral propranolol, given in incremental doses, produced a moderate but significant lowering of blood pressure which was correlated with the concentration of propranolol in plasma. 2. Propranolol also reduced plasma renin activity (PRA) in the supine posture, on standing and after intravenous frusemide. However, 'supine' and 'frusemide' PRA values were markedly reduced at a plasma concentration of propranolol that had little effect on blood pressure. 3. On administration of propranolol there was little correlation between blood pressure decrease and PRA suppression, and even less between pretreatment PRA values and hypotensive response. 4. It is concluded that in patients with mild and moderate hypertension and low or normal plasma renin activity, suppression of PRA is not an important determinant of the hypotensive response to propranolol.

Administration, Oral↗
PubMed1975

Studies of the absorption and removal of propranolol in hypertensive patients during therapy.

The variability of plasma propranolol concentrations has been determined in a large group of patients being treated with the drug. Although the average patient achieved a therapeutic plasma level with 160 mg/day, there was marked interpatient variation. This was found to be primarily the result of differences in effective absorption of the drug, which averaged 46% of the oral dose but ranged from 20 to 80%. Propranolol disappeared from plasma with a half-life of 4.7 hours and its removal appeared to follow dose independent kinetics with no evidence of saturation of hepatic metabolism. The derived pharmacokinetic values of volume of distribution and clearance rate have been used to provide guidelines for initiating propranolol therapy intravenously, and the schedule of 8 mg as a loading dose and 0.02 mg/min as a sustaining dose has been suggested.

Administration, Oral↗
PubMedDate not supplied

Cryoactivation fails to augment plasma renin activity in the cat.

1. Active and cryoactivated renin (plasma renin) activity after incubation at -5 degrees C for 4 days, were measured in cat plasma sampled before and during the following procedures: suprarenal aortic stenosis, electrical stimulation of the pons and mild hypotensive haemorrhage. 2. Under all experimental conditions the values of plasma renin activity for both the activated and non-activated samples were similar. 3. The absence of a cryoactivatable aliquot of renin suggests that in cat plasma the inactive form of the enzyme either is actually absent or has a liability to the action of cold different than in other animal species.

Animals↗